Skip to main content
Caplight Logo









Vesalius Therapeutics

Vesalius Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.vesaliustx.com/

Last Round

Strategic

Nov 12, 2024

Total Funding Raised

$155M

Company Overview

Vesalius Therapeutics is a biotechnology company that develops a drug discovery platform to identify genetic circuits driving common illnesses and create patient-derived models for screening drug candidates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision medicinedrug discoverybiotechnologyDIAMOND platformbiotech startuptherapeutic developmentpatient subpopulationhealthcare analyticsAI drug discoverycomputational biologyin silico drug discoverybiopharma R&Dmolecular network discoverydrug pipelineFlagship-backed

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vesalius Therapeutics Comparables

Compare Vesalius Therapeutics with similar companies based on industry and business-model similarity.

Vesalius Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Empress Therapeutics
84%
Quotient Therapeutics
83%
PrecisionLife
82%

Vesalius Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 12, 2024
Series AMar 2, 2022

Key People

Founding team and executive leadership

Yasir Al-Wakeel

Chief Executive Officer

Executive Team

Vesalius Therapeutics Investors

Notable investors and investment history

Vesalius Therapeutics investors
InvestorRounds
Flagship PioneeringSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 16, 2025

    Yasir Al-Wakeel appointed as the new Chief Executive Officer.

  • Dec 31, 2024

    Partnered with GSK to develop novel therapies for Parkinson's disease.

Vesalius Therapeutics Filings

Explore SEC and related filing metadata, where available.

Vesalius Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vesalius Therapeutics's valuation, stock price, and market status.

Is Vesalius Therapeutics a public or private company?

Vesalius Therapeutics is a private company.

What is the current stock price of Vesalius Therapeutics?

Vesalius Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Vesalius Therapeutics worth (valuation)?

Valuation information for Vesalius Therapeutics is not publicly available.

Can I buy Vesalius Therapeutics stock?

Vesalius Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vesalius Therapeutics's last funding round?

Vesalius Therapeutics's most recent funding round was Strategic on November 12, 2024.

Who are the main investors in Vesalius Therapeutics?

Key investors in Vesalius Therapeutics include Flagship Pioneering.

Will Vesalius Therapeutics IPO soon?

No public IPO plans have been announced for Vesalius Therapeutics.

How can I track Vesalius Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vesalius Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range29
Year Founded2019
Last FundingNov 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?